Trial Profile
An Open-label, Multicenter, Phase II Study of PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or Without Actionable Genetic Abnormalities, Detected Using NGS Platform
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2022
Price :
$35
*
At a glance
- Drugs Spartalizumab (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Oct 2018 New trial record
- 01 Oct 2018 Status changed from not yet recruiting to recruiting.